成人抗血栓药物相关颅内出血的治疗:神经重症监护学会与重症医学学会的聚焦指南更新
该聚焦指南更新由神经重症监护学会联合重症医学学会制定,在2016版指南发布后评估新证据,围绕五个PICO问题系统评价并荟萃分析,采用GRADE方法形成八条推荐。主题包括:口服Xa因子抑制剂相关出血中andexanet alfa与4F-PCC的选择、抗血小板药物使用下血小板输注与不输注、去氨加压素的使用、小量自发性脑实质出血中是否治疗抗凝效应、以及黏弹性止血试验指导创伤性颅内出血凝血病治疗。推荐均为条件性推荐,需结合患者临床状态和个体因素考虑。
要点
- 对Xa因子抑制剂抗凝效应相关急性颅内出血,条件性推荐使用4F-PCC而非andexanet alfa。
- 对使用抗血小板药物的非神经外科自发性脑实质出血患者,条件性推荐避免血小板输注。
- 对使用阿司匹林的自发性脑实质出血患者若接受手术,条件性推荐输注血小板。
- 对创伤性颅内出血凝血病,条件性推荐使用黏弹性止血试验指导治疗。
- 血小板输注用于创伤性颅内出血抗血小板效应、去氨加压素用于抗血小板效应、小量脑实质出血治疗抗凝效应,专家组未能给出推荐。
适用人群与场景
- 成人急性颅内出血患者,包括自发性脑实质出血和创伤性颅内出血,且与抗血栓药物使用相关。
处置流程与药物剂量
- 对Xa因子抑制剂抗凝效应相关急性颅内出血,条件性推荐使用4F-PCC而非andexanet alfa。
- 对使用抗血小板药物的非神经外科自发性脑实质出血患者,条件性推荐避免血小板输注。
- 对使用阿司匹林的自发性脑实质出血患者若接受手术,条件性推荐输注血小板。
- 对创伤性颅内出血凝血病,条件性推荐使用黏弹性止血试验指导治疗。
研究设计与关键结果
- 制定机构为神经重症监护学会与重症医学学会,在2016版指南发布后评估新证据,生成五个PICO问题并系统评价与荟萃分析,采用GRADE方法形成八条推荐。
- 四个PICO问题涉及:andexanet alfa与4F-PCC治疗口服Xa因子抑制剂效应、抗血小板药物使用下血小板输注与不输注、去氨加压素与不去氨加压素、小量自发性脑实质出血中治疗抗凝效应与不治疗、黏弹性止血试验指导创伤性颅内出血凝血病治疗。
- 专家组就血小板输注用于创伤性颅内出血抗血小板效应、去氨加压素用于抗血小板效应、小量脑实质出血治疗抗凝效应三个问题未能给出推荐。
证据类型、等级与局限
- 证据类型:指南(聚焦更新),采用GRADE方法分级,推荐均为条件性推荐。
- 局限:原文未报告局限性
对床旁实践的改变
- 对Xa因子抑制剂相关急性颅内出血,条件性推荐选择4F-PCC而非andexanet alfa,需结合患者临床状态和个体因素考虑。
- 对使用抗血小板药物的非神经外科自发性脑实质出血患者,条件性推荐避免血小板输注。
- 对使用阿司匹林的自发性脑实质出血患者若接受手术,条件性推荐输注血小板。
- 对创伤性颅内出血凝血病,条件性推荐使用黏弹性止血试验指导治疗。
指南或共识出处
- 指南名称:Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and the Society of Critical Care Medicine;发布机构:神经重症监护学会与重症医学学会;发表于Neurocrit Care。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Antithrombotic-associated intracranial hemorrhage (ICH) is a life-threatening condition, and rapid treatment in the setting of antithrombotic agents may limit hematoma expansion and improve outcomes. This focused update evaluated the available evidence after publication of the 2016 guidelines.
METHODS: The Neurocritical Care Society, in conjunction with the Society of Critical Care Medicine, generated five questions to guide a systematic review and meta-analysis. Three of these questions update prior recommendations, while two are newly introduced. Each question followed a Population, Intervention, Comparator, Outcome (PICO) framework and focused on the management of acute ICH including spontaneous intraparenchymal hemorrhage (IPH) and traumatic ICH. The topics addressed were: (1) andexanet alfa versus 4-factor prothrombin complex concentrate (4F-PCC) for treatment of oral factor Xa inhibitor effects; (2) platelet transfusion versus no transfusion for treatment in the setting of antiplatelet agent use; (3) desmopressin versus no desmopressin for treatment in the setting of antiplatelet agent use; (4) treatment of anticoagulant effects versus no treatment in the setting of small IPH; and (5) use of viscoelastic hemostatic assays (VHAs) to treat coagulopathy in traumatic ICH. Recommendations were developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.
RESULTS: The panel generated eight recommendations. For patients with acute ICH, the panel issued the following conditional recommendations: use 4F-PCC rather than andexanet alfa for the treatment of the anticoagulant effects of factor Xa inhibitors, avoid platelet transfusion in non-neurosurgical patients with spontaneous IPH on antiplatelet agents, administer platelet transfusion in patients with spontaneous IPH on aspirin who are undergoing surgery, and use VHAs to guide treatment of coagulopathy in traumatic ICH. The panel was unable to issue recommendations regarding platelet transfusion for treatment of antiplatelet effects in traumatic ICH, use of desmopressin for treatment of antiplatelet effects, or treatment of anticoagulant effects in small IPH.
CONCLUSIONS: The guideline writing panel provided new conditional recommendations for the treatment of antithrombotic-associated acute ICH. These recommendations are intended for consideration along with the patient's clinical status and patient-specific factors.
参考来源
- Vallejo MC, Kennedy LS, Dengler B, et al. Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and the Society of Critical Care Medicine. Neurocrit Care. 2026. PMID: 42786382. doi:10.1007/s12028-026-02601-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。